Find information on Industry Analysis Report

Posts tagged ‘World’

Report on World Subsea Vessel Operations Market Forecast

This report forecast that between 2012 and 2016 $77bn will be spent on subsea vessel operations in field development, inspection, repair & maintenance (IRM) and subsea well intervention. This is an increase of 63% over the preceding five-year period, with global vessel demand for these markets expected to increase 33%.

This strong growth is a result of confidence returning to the subsea industry, a move towards deep water in underdeveloped regions and towards ultra deep in those already developed, and the subsequent increased demand for higher specification vessels required for these operations.

The World Subsea Vessel Operations Market Forecast 2012-2016 analyses the main factors driving demand for ROVSV, DSV, Flexlay, LWIV and Pipelay Vessels. The new edition contains:

Market forecasting & field prospect data – the report uses a unique market model specifically developed in collaboration with leading subsea industry participants. Based on the DW proprietary databases covering vessels and offshore oil and gas developments, the report includes a market forecast with an unmatched level of detail and presents analysis based on unique data.
Macro-economic indicators – a review of those influencing subsea markets including growing global energy demand and oil consumption, oil supply pressures, the role of deepwater, oil & gas prices drivers & forward assumptions and E&P expenditure.
Vessel fleet supply-side analysis – global vessel supply trends for DSVs, ROVSVs, Flexlays, Pipelays and LWIVs with historic vessel deliveries from 1965-2012 and vessel supply expressed in total vessel days, split by type.
Comprehensive analysis – of vessel demand for key subsea sectors from 2007-2016. Expenditure and vessel day demand broken out by field development, IRM and well intervention.
Regional analysis – expenditure and vessel demand by market with trend commentary and speedreads for Africa, Asia, Australasia, Eastern Europe & FSU, Latin America, Middle East, North America, Norway, UK and Rest of Western Europe.

Why buy the report?
The World Subsea Vessel Operations Market Forecast 2012-2016 is an excellent source of information for those seeking a timely update on this dynamic and rapidly changing industry. Geared to senior executives’ needs, the report assumes no previous knowledge of the subject area. The report provides the reader with a comprehensive understanding of the key trends involved in shaping the requirement for subsea vessels.

Concise report layout – industry background and supporting materials condensed to enable quick review
The report is essential for financial institutions, equipment manufacturers, offshore engineering, construction, operations & maintenance companies and contractors, drilling operators, oil & gas companies and agencies & government departments wanting to make more informed investment decisions.

Table of Contents
Executive Summary & Conclusions
Market Expenditure Summary
Global Vessel Supply & Demand

Macro-Economic Overview
Global Energy Supply & Demand
Move to Offshore
Role of Deepwater
Oil & Gas Price – Drivers and Forward Assumptions
E&P Expenditure

Definitions & Terminology
Markets
Vessel Tasks & Definitions
Vessel Activity by Type

For more information kindly visit :
Report on World Subsea Vessel Operations Market Forecast

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
http://3marketresearchreport.blogspot.in/

Research Report on World Medical Market Forecasts

The global market for medical equipment and supplies as defined in this report is valued at US$307.7 billion in 2012, equal to just under US$50 per capita. Several years of rapid growth came to a halt amid the economic downturn towards the end of 2008 and into 2009. Many countries experienced a slowdown in the market in 2009, with especially poor performance in the USA and Europe. Much of the world has seen a swift return to growth in 2010 and 2011, however, with the major exception of the Eurozone, which continues to perform relatively poorly.

The CAGR for the 2007-2011 period was 7.9%, although this masks the major reduction in growth which occurred in 2009 and 2010. Market growth resumed in 2011, although it will not be quite as rapid as before the economic downturn. Espicom projects that the total market will rise to US$434.4 billion by 2017, equal to just underUS$67 per capita and a CAGR for the 2012-17 period of 7.1%. Some of the best prospects for growth will be in the developing markets of Asia, Latin America and Central/Eastern Europe, while traditional Western markets represent more steady performers.

Use this new report to easily answer questions such as:
Which Asian countries offer the best opportunities for market growth and in which sectors?
Which Eurozone medical sector is set to exceed US$32 billion and a 2012-17 CAGR of 7%?
What are the prospects for MRI in Latin America and which countries offer the best opportunities?
How did the Chinese orthopaedic sector fare in 2011 and what are its prospects to 2017?

This important business evaluation provides:
Growth forecasts to 2017 for 86 markets – 20 more than last edition
Comparative data on a regional and global basis
Rankings by key indicators allow “at a glance” benchmarking of countries
Detailed information on each market
This report is available in pdf or print formats with Espicom Interactive web access for all customers
Practical value as all tables and graphs can be easily exported to be included in your own reports and data sets

This new report provides detailed market forecasts
Worldwide Medical Markets Forecasts to 2017 is essential for business forecasters, marketing planners and the investment community. Anyone, in fact, who needs to understand the future outlook for the dynamic medical device and equipment industry.

In 416 information-packed pages the report provides thousands of market projections, rankings and comparisons.

Provided with global, regional and national views
A global overview of key rankings

Six regional sections allow comparative assessment of countries within a geographic region:
Western Europe
Central & Eastern Europe
Middle East/Africa
Asia/Pacific
Americas
Sub Saharan Africa
Individual markets to provide detail and forecasts at a national level

For more information kindly visit :
Research Report on World Medical Market Forecasts

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
http://twitter.com/#!/bharatbook
http://retailmarketresearch.blogspot.com/

Research Report on The World Pharmaceutical Markets

The World Pharmaceutical Market Fact Book 2012 is the ideal companion in today’s challenging pharmaceutical market environment. The need to understand world pharmaceutical marketplaces, and be able to answer quickly those questions that arise daily, is essential. That is why this current and comprehensive source of key market
statistics is an invaluable aid for every pharmaceutical industry executive.

Proven and reliable
Published by Espicom, for over 30 years experts in the healthcare market field, the 350-page Fact Book brings together a range of often difficult to source information in one
single, convenient and comprehensive publication. Keep it near to you at all times.

The World Pharmaceutical Markets Fact Book 2012 quickly answers key market questions
Which country spends most on pharmaceuticals as a % of GDP?
How are the economic downturn and currency fluctuations affecting expenditure in key markets?
Which pharmaceutical sectors are growing the fastest and where?
How does the Brazilian market compare with Mexico and Argentina in terms of total health expenditure?
What demographic development is affecting the market in Central and Eastern Europe?
What have been the key trends affecting pharmaceutical companies in leading emerging markets such as India, China, Brazil and Russia?

Which other business reference provides…
Key economic, demographic and health statistics on 66 markets around the world
Five years of historical data for markets, GDP & healthcare spending,demographics and healthcare statistics
World/regional overviews plus statistics on individual countries
Over 500 tables and charts
PDF format with Espicom Interactive online access included included in the price. Print option available

Comprehensive Contents
World Overview
Pharmaceutical market (actual and per capita)
Trade in pharmaceutical markets
Economic data and health expenditure
Demographics
Healthcare data
– Hospital and beds
– Admissions and surgical procedures
– Physicians, nurses, pharmacists and dentists

Regional Overviews
The report provides 5 regional overviews for:
Americas
Asia/Pacific
Central/Eastern Europe
Middle East/Africa
Western Europe

Which provide data on:
Market data by product sector
Trade data
Economic data
Demographics
Health expenditure
Healthcare data
Hospital and beds
Admissions and surgical procedures
Physicians, nurses, pharmacists and dentists

Key facts and figures for 66 markets:
Market Data: 2006-2011

Actual and Per Capita
Trade Data: 2006-2011
Imports/Import growth rate
Exports/Export growth rate

Economic Data: 2006-2011
Health expenditure (US$ billions)
Health expenditure per capita (US$)
Health expenditure as a % of GDP
Public health expenditure as a % of the total

Demographic Data: 2006-2011
Population
Population growth
% population aged 65+
Live births per ’000 population
Deaths per ’000 population
Infant mortality per ‘000 live births
Life expectancy for males/females

Healthcare Data: 2006-2011
Hospitals (public and private)
Hospital beds
Beds per ‘000 population
Inpatient admissions
Inpatient admissions per ‘000 population
Average length of stay (days)
Surgical procedures (‘000’s)
Outpatient visits
Outpatient visits per ‘000 population
Nurses per ‘000 population
Physicians per ‘000 population
Dentists
Dentists per ‘000 population
Pharmacists
Pharmacists per ‘000 population

For more information kindly visit :
Research Report on The World Pharmaceutical Markets

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
http://twitter.com/#!/bharatbook
http://retailmarketresearch.blogspot.com/

Stem Cell Technologies: World Market Outlook 2012-2022

Why the stem cells market will expand – discover its commercial potential
What does the future hold for stem cells in medicine? Visiongain’s report shows you potential revenues to 2022, assessing data, trends, opportunities and prospects there.

That new study lets you assess projected sales at world market and submarket level. You see discussions of work on stem cells in leading countries too – outlooks, challenges, patenting and regulations.
You see forecasting of world-level submarkets to 2022, finding potential revenues:
Stem cell therapies
• Stem cell banks (e.g., cord blood banking)
• Ancillaries – adjunct technologies.

The technology is changing medicine through new therapies, methods and applications in drug development. Its scope is vast and promising, despite challenges.

With our study you also assess the R&D pipeline, seeing trends and outlooks. You find discussions of treatments in development, by therapeutic area and organization:
• Autoimmune diseases – modifying the immune system
• Diabetes – restoring pancreatic function
• Oncology and cancer treatment
• Cardiovascular diseases – healing the heart and vascular system
• Neurological and cerebrovascular disorders – regenerating CNS tissue
• Ophthalmic disorders – potential for overcoming sight loss
• Bioartificial livers and hepatic regeneration with stem and progenitor cells
• Dermatology – developments in cellular skin repair
• Adipose-derived stem cells for autologous treatments
• Regenerative dentistry – potential for biotechnological tooth replacement.

You find prospects for embryonic, adult and induced pluripotent stem cells from 2012.
Market value for 2014 and prospects for the future
What will happen next? The biotechnology industry will develop many products using stem cells and increase revenues there from 2012 to 2022. The R&D pipeline is extensive. Overall world revenue will reach $7.3bn in 2014, our report forecasts.

Expansion of the market will result from new stem cell treatments and increased uptake of those technologies in drug development assays.
A diverse pipeline of therapies offers hope for treating many diseases. There are potential cures for diabetes, HIV and dry age-related macular degeneration (AMD).

Stem cell-based innovations tackle cardiovascular disorders, autoimmune diseases, metabolic disorders and many other conditions. Some of the breakthroughs will be a commercial reality by 2022, our investigation predicts.

What are companies doing? Our work profiles 187 organisations and investigates prospects of the industry and market. Examples include these developers and producers:
• Advanced Cell Technology
• Athersys
• Baxter Healthcare
• Bioheart
• Cytori Therapeutics
• Gamida Cell
• Mesoblast
• NeoStem
• Osiris Therapeutics
• TiGenix.

The scope of the field is widening, with many organisations entering and collaborating. You see how.
Haematopoietic stem cell transplantation is an established treatment. Revenues from transplants of bone marrow, peripheral blood and umbilical cord blood form much of the market in 2012. Those activities form a beginning, with many advances possible by 2020.
There are many commercial opportunities in stem cells, with high revenues possible from 2012 to 2022. New products will change medicine. Our report shows you and explains.
Forecasts, market shares, developmental trends, commercial news and discussions
In visiongain’s report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP), company profiles and discussions of R&D activities. You receive 40 tables, 20 charts and six research interviews.

For more information kindly visit :
Stem Cell Technologies: World Market Outlook 2012-2022

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
http://in.linkedin.com/in/bharatbook
http://healthcareraj.blogspot.com/

Neuroprotective Products: World Market Prospects 2012-2022

Your guide to trends and revenue prospects in neuroprotection
What are the commercial prospects for neuroprotective treatments? Visiongain’s new report shows you potential revenues and trends to 2022, discussing data, opportunities and outlooks.
Many neuroprotective products are in development. Our study lets you assess projected sales at overall world market, therapeutic submarket and product level to 2022.
The protection of nerve tissues is becoming more important. You can assess the potential for drug revenues there, as well as finding discussions of stem cells and gene therapy.
In particular, how will 11 products – including Rasagiline, Minocycline, Memantine and NeuroSTAT – perform to 2022? Our investigation gives you business research and analysis with sales forecasts.

You also see forecasting of five world-level submarkets to 2022, finding potential revenues:
• Ion channel modulators
• Mitochondrial dysfunction regulators
• Anti-inflammatory and anti-apoptotic agents
Neurotrophic factors
• Other neuroprotective treatments.

Our study lets you assess the R&D pipeline, seeing trends and prospects. You find data and discussions on developmental topics:
• Alzheimer’s disease
• Parkinson’s disease
• Multiple sclerosis
• Brain injury
• Ocular degeneration (retinal disorders)
• Huntington’s disease
• Amyotrophic lateral sclerosis (ALS)
• Neuropathies
• Other disorders affecting the nervous system.

The neuroprotection market offers strong opportunities for medicines to slow disease progression, protecting the central nervous system (CNS). Our report shows and explains.

Market value for 2014 and outlook for the future
What does the future hold? The pharma industry will develop more drugs for neuronal protection, with high revenues possible this decade and beyond. The R&D pipeline is strong and promising. Overall world revenues will reach $2.6bn in 2014, our report forecasts.

We predict that the neuroprotection market will achieve strong revenue growth to 2022, especially from 2017. By then, many clinical trials will have finished and products will gain regulatory approval. You see prospects for novel drugs.

Rising incidence and prevalence of neurodegenerative diseases in ageing populations will stimulate that treatment market. Also stimulating the industry and market will be the treatment of brain injuries, especially those from traffic accidents.

What are companies doing? Our work discusses Ceregene, Genervon Biopharmaceuticals, Neuren Pharmaceuticals and others, evaluating commercial prospects. The scope of the field is widening, with many organisations entering and collaborating.

The aim of drug developers is to prevent neuronal death and revive damaged neurons (neuroregeneration). However, not all neuroprotective agents will be neuroregenerative, the study predicts.
Regulatory agencies recognise the therapeutic potential of neuroprotective agents and have given fast track designation and orphan drug status to candidates.
You can investigate the future of neuroprotection now, discovering revenue potential and other prospects.
Sales forecasts, market shares, developmental trends and discussions
In visiongain’s report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP) and discussions of R&D activities. You receive 46 tables, 22 charts and two research interviews.

Nine ways Neuroprotective Products: World Market Prospects 2012-2022 helps you

In particular, our study gives you the following knowledge on the topic:
• Find potential revenues to 2022 for the world market and submarkets
• Discover projected revenue trends of 11 leading products to 2022
• See predictions of launch times for prominent drug candidates
• Assess 7 leading companies, and other players, discovering activities and outlooks
• Review R&D pipelines, seeing trends by therapeutic area and organisation
• Investigate competition and opportunities influencing sales
• Find out what will stimulate and restrain the industry and market
• Analyse prospects for established companies and those seeking to enter the sector
• View opinions from our survey, seeing interviews with authorities in industry.

For more information kindly visit :
Neuroprotective Products: World Market Prospects 2012-2022

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
http://bharatbook.posterous.com/
http://healthcareraj.blogspot.com/

Hepatitis Treatments and Vaccines: World Market 2012-2022

How to find trends and revenue prospects for hepatitis-treating agents
Where is the hepatitis treatment market heading? Visiongain’s new report shows you potential revenues and trends to 2022, discussing data, opportunities and prospects.
This study investigates drugs and vaccines for treating hepatitis – existing and pipeline products. You assess projected sales at world market, therapeutic submarket, product and national level to 2022.

You see forecasting of therapeutic submarkets to 2022, finding potential revenues:
Hepatitis B
• Hepatitis C.

You also find revenue forecasting of product classes to 2022:
• Oral antivirals
• Interferons
• Vaccines.

How will 10 leading products – including Baraclude, Pegasys, Incivek and PegIntron – perform from 2012? Our investigation gives you business research and analysis with sales forecasts for leading brands. You discover their growth potential.

The market is changing. You find discussions of treatments in development, by phase and indication. In the study you also see predictions of launch times for product candidates.

Market value for 2012 and prospects for the future
What does the future hold? The pharma industry will improve treatments for hepatitis and increase revenues there from 2012 to 2022. In particular, the R&D pipeline for hepatitis C is strong and promising. World revenues will grow to $8.7bn in 2012, our analysis shows.
We estimate that more than 15 new therapies will reach the market by 2016. Almost all of those pipeline candidates are oral direct-acting antivirals. You see opportunities there.
What about companies? Our work discusses Roche, GSK, Bristol-Myers Squibb, Merck, Novartis and many other pharmaceutical manufacturers, analysing prospects of the industry.

The main goal for hepatitis C therapy is all-oral, interferon-free regimens with improved efficacy over present treatments. Companies are developing oral antiviral combinations, with launches expected towards the middle of this decade.

High rates of efficacy and barriers to resistance in leading treatments mean the world hepatitis B treatment market will grow strongly to 2016, our report predicts. Generic competition will become noticeable afterwards, however.

Unmet treatment needs in hepatitis C, expanding vaccination programmes in emerging national markets, and increased virus screening will also stimulate the world market from 2012 onwards, we find.
Many commercial opportunities for hepatitis-treating agents exist, with high revenues possible to 2022. Our report shows you and explains.
Sales forecasts, market shares, developmental trends and discussions
In visiongain’s report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP) and discussions of R&D activities. You receive 80 tables, 64 charts and a research interview.

Eight ways Hepatitis Treatments and Vaccines: World Market 2012-2022 helps you

In particular, our study gives you the following knowledge on the topic:
• Find potential revenues to 2022 for the world market and submarkets
• Discover projected revenue trends of 10 leading brands to 2022
• See market forecasting to 2022 for the US, Japan, EU5 countries, China and India
• Assess 7 leading companies, and other players, discovering activities and outlooks
• Review R&D pipelines, seeing trends by therapeutic area
• Investigate competition and opportunities influencing sales
• Find out what will stimulate and restrain the industry and market
• View opinions from the sector, seeing an interview with an external authority.

There, you discover quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed on business intelligence.
Without our report you could miss out on information that your competitors use.
Gain research and analysis now for the treatment and prevention of hepatitis
Our study is for everybody needing industry and market analyses for hepatitis-treating drugs and vaccines. You find data, trends and answers there.

For more information kindly visit :
Hepatitis Treatments and Vaccines: World Market 2012-2022

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
http://bharatbook.posterous.com/
http://healthcareraj.blogspot.com/

World Combined Heat & Power (CHP): Micro, Small and Large-Scale

Combined heat and power (CHP) systems were responsible for just under 10% of global electrical power generation capacity in 2011. CHP is a set of power generation technologies that provides both heat in the form of steam or hot water and electricity from a single system. These systems include a prime mover to convert fuel into electricity, a heat recovery steam generator (HRSG) to generate the process heat and perhaps a boiler if the system burns coal or wood waste to run a steam turbine.

The CHP market has been driven by China in the last five years, as that country’s fast paced electrical generation capacity increases have significantly bolstered the CHP market in the country. However, China’s power capacity growth is slowing, resulting in an essentially flat global CHP market between 2007 and 2011, posting a compound annual growth rate (CAGR) of just 0.4% for the period to reach a value of $19.3 billion. The CHP market has been much stronger in the U.S. and Germany, with both countries achieving near 20% CAGR between 2007 and 2011. The small-CHP market has experienced an incredible CAGR of 24.8% in the same period on the strength of micro-CHP (under 5 kW) sales in Japan and small-CHP (up to 1 MW) sales in Germany.

Spark spread and government incentives are the two main driving forces behind the CHP market, although each has a different effect for different market segments. The U.S. market has been up and down over the period, and has been lower than what was experienced in the first part of the decade, because of the lack of strong government support and dropping natural gas prices. Germany, on the other hand, has a strong feed in tariff policy that is continuing to drive the CHP market in the country and will continue to do so in the long term. In Japan, exceptionally large subsidies for micro-CHP systems continue to accelerate that segment of the CHP market in the country.

Natural gas turbines continue to provide most CHP electricity generation in the U.S. and Europe, but it is reciprocating engine-based CHP systems that are the most numerous. The most common type of fuel in use for CHP systems in most countries is natural gas. The major exception is China where coal is still the dominant fuel being used in many of the country’s district heating systems. Countries such as Sweden, Switzerland, Norway and Finland have over 30% of CHP electricity generation from renewable fuels such as wood waste and municipal waste.

The CHP market will continue to experience slow growth over the next five years. However, SBI Energy expects global electricity costs to rise faster than the cost of natural gas in the long term, leading to a much stronger CHP market through the end of the decade. By 2021, there will be 651 gigawatts (GW) of CHP capacity installed worldwide, and the global CHP market will be worth $43.1 billion. The small-CHP segment will continue to grow faster than the overall CHP market, achieving a CAGR of 12.2% between 2012 and 2021 and growing to be worth a little over 6% of the global CHP market.

For more information kindly visit :
World Combined Heat & Power (CHP): Micro, Small and Large-Scale

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
http://researchbook.typepad.com/blog/
http://energyresourcesreport.blogspot.in/

Tag Cloud